2021 药师共识指南:类风湿关节炎患者生物制剂过渡的监测

2021-09-14 国外药师专家小组(统称) Pharmacy Practice

近期关于小分子JANUS激酶抑制剂(JAKi)等新兴药物的获批,结合生物仿制药的出现,扩展了类风湿关节炎(RA)的治疗选择。本文主要针对JA患者生物制剂治疗过渡的监测提供指导。

中文标题:

2021 药师共识指南:类风湿关节炎患者生物制剂过渡的监测

英文标题:

Monitoring the transition of patients on biologics in rheumatoid arthritis: Consensus guidance for pharmacists

发布日期:

2021-09-14

简要介绍:

近期关于小分子JANUS激酶抑制剂(JAKi)等新兴药物的获批,结合生物仿制药的出现,扩展了类风湿关节炎(RA)的治疗选择。本文主要针对JA患者生物制剂治疗过渡的监测提供指导。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 药师共识指南:类风湿关节炎患者生物制剂过渡的监测.pdf)] GetToolGuiderByIdResponse(projectId=1, id=f15e11c002201908, title=2021 药师共识指南:类风湿关节炎患者生物制剂过渡的监测, enTitle=Monitoring the transition of patients on biologics in rheumatoid arthritis: Consensus guidance for pharmacists, guiderFrom=Pharmacy Practice, authorId=0, author=, summary=近期关于小分子JANUS激酶抑制剂(JAKi)等新兴药物的获批,结合生物仿制药的出现,扩展了类风湿关节炎(RA)的治疗选择。本文主要针对JA患者生物制剂治疗过渡的监测提供指导。, cover=https://img.medsci.cn/20211011/1633920665502_5579292.jpg, journalId=0, articlesId=null, associationId=1518, associationName=国外药师专家小组(统称), associationIntro=, copyright=0, guiderPublishedTime=Tue Sep 14 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>近期关于小分子JANUS激酶抑制剂(JAKi)等新兴药物的获批,结合生物仿制药的出现,扩展了类风湿关节炎(RA)的治疗选择。本文主要针对JA患者生物制剂治疗过渡的监测提供指导。</p>, tagList=[TagDto(tagId=457, tagName=类风湿关节炎)], categoryList=[CategoryDto(categoryId=11, categoryName=药械, tenant=100), CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=457, guiderKeyword=类风湿关节炎, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2473, appHits=173, showAppHits=0, pcHits=470, showPcHits=2292, likes=1, shares=17, comments=2, approvalStatus=1, publishedTime=Mon Oct 11 11:08:16 CST 2021, publishedTimeString=2021-09-14, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Oct 11 10:53:37 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 05:49:59 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 药师共识指南:类风湿关节炎患者生物制剂过渡的监测.pdf)])
2021 药师共识指南:类风湿关节炎患者生物制剂过渡的监测.pdf
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1064330, encodeId=ddbf106433092, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27a5649816, createdName=ms6000001997892366, createdTime=Wed Oct 27 11:38:07 CST 2021, time=2021-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059411, encodeId=2c7f10594110b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47445626421, createdName=ms6000001387765207, createdTime=Mon Oct 11 11:43:30 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
    2021-10-27 ms6000001997892366

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1064330, encodeId=ddbf106433092, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27a5649816, createdName=ms6000001997892366, createdTime=Wed Oct 27 11:38:07 CST 2021, time=2021-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059411, encodeId=2c7f10594110b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47445626421, createdName=ms6000001387765207, createdTime=Mon Oct 11 11:43:30 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
    2021-10-11 ms6000001387765207

    学习了

    0

拓展阅读

2010 BSR/BHPR 类风湿关节炎中抗肿瘤坏死因子疗法的安全指引

英国风湿病学会(BSR,British Society for Rheumatology) · 2010-01-01

2010版类风湿关节炎诊断及治疗指南

中华医学会风湿病学分会(CRA,Chinese Rheumatology Association) · 2010-04-01

2010 依那西普治疗类风湿关节炎和强直性脊柱炎的专家建议

中国风湿免疫科相关专家小组(统称) · 2010-06-30

2010 ACR/EULAR 类风湿关节炎分类标准

美国风湿病学会(ACR,American College of Rheumatology) · 2010-09-01

2011 BSR/BHPR 指南:使用利妥昔单抗治疗类风湿关节炎

英国风湿病学会(BSR,British Society for Rheumatology) · 2011-01-01

2011SIGN 苏格兰国家类风湿关节炎早期治疗临床指南

苏格兰校际指南网络(SIGN,Scottish Intercollegiate Guidelines Network) · 2011-01-01